Premium
Cellular immune modulation after a single high dose of levamisole in patients with carcinoma
Author(s) -
Lewinski Uri H.,
Mavligit Giora M.,
Hersh Evan M.
Publication year - 1980
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19801115)46:10<2185::aid-cncr2820461015>3.0.co;2-5
Subject(s) - levamisole , medicine , immune system , in vivo , lymphocyte , antigen , immunology , cellular immunity , immunostimulant , drug , pharmacology , immune modulation , microgram , in vitro , immunotherapy , biology , biochemistry , microbiology and biotechnology
The effect of a single high dose of Levamisole (200 mg/M 2 ) on delayed‐type hypersensitivity (DTH) in vivo and on lymphocyte blastogenesis to mitogens and antigens in vitro was studied in 26 patients with carcinoma. Similar studies were conducted in 24 control patients. Levamisole had a moderate but significant enhancing effect on DTH to Dermatophytin detectable no earlier than eight hours and still present at 48 hours after the drug administration. A moderate but significant enhancing effect on lymphocyte blastogenesis to mitogens and antigens was also demonstrated during the same time sequence. Further clinical trials with Levamisole should be conducted with more attention paid to schedule of drug administration.